Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML …
S Luatti, F Castagnetti, G Marzocchi… - Blood, The Journal …, 2012 - ashpublications.org
Additional chromosomal abnormalities (ACAs) in Philadelphia-positive cells have been
reported in∼ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in …
reported in∼ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in …
Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic …
E Jabbour, HM Kantarjian, LV Abruzzo… - Blood, The Journal …, 2007 - ashpublications.org
The development of chromosomal abnormalities (CAs) in the Philadelphia chromosome
(Ph)–negative metaphases during imatinib (IM) therapy in patients with newly diagnosed …
(Ph)–negative metaphases during imatinib (IM) therapy in patients with newly diagnosed …
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib
M Loriaux, M Deininger - Leukemia & lymphoma, 2004 - Taylor & Francis
Treatment of chronic myeloid leukemia (CML) with imatinib (Gleevec®) induces a much
higher rate of partial and complete cytogenetic responses (CCR) than interferon-α (IFN) …
higher rate of partial and complete cytogenetic responses (CCR) than interferon-α (IFN) …
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid …
C Terre, V Eclache, P Rousselot, M Imbert, C Charrin… - Leukemia, 2004 - nature.com
Imatinib mesylate (Gleevec®), an inhibitor of the BCR-ABL tyrosine kinase, was introduced
recently into the therapy of chronic myeloid leukemia (CML). Several cases of emergence of …
recently into the therapy of chronic myeloid leukemia (CML). Several cases of emergence of …
The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations
AN Mohamed, P Pemberton, J Zonder, CA Schiffer - Clinical cancer research, 2003 - AACR
Abstract Purpose and Experimental Design: The acquisition of secondary chromosomal
aberrations in chronic myeloid leukemia (CML) patients with Philadelphia chromosome …
aberrations in chronic myeloid leukemia (CML) patients with Philadelphia chromosome …
The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib …
SE Lee, SY Choi, JH Bang, SH Kim, E Jang, JY Byeun… - Cancer genetics, 2012 - Elsevier
The aim of this study was to evaluate the long-term clinical significance of an additional
chromosomal abnormality (ACA), variant Philadelphia chromosome (vPh) at diagnosis, and …
chromosomal abnormality (ACA), variant Philadelphia chromosome (vPh) at diagnosis, and …
Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia …
J Medina, H Kantarjian, M Talpaz, S O'Brien… - Cancer, 2003 - Wiley Online Library
BACKGROUND Anecdotal cases of chromosomal abnormalities in Philadelphia
chromosome (Ph)‐negative metaphases have been reported in patients with chronic …
chromosome (Ph)‐negative metaphases have been reported in patients with chronic …
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression
S Marktel, D Marin, N Foot, R Szydlo, M Bua… - …, 2003 - haematologica.org
BACKGROUND AND OBJECTIVES: The acquisition of additional cytogenetic changes
(clonal evolution, CE) during treatment of chronic myeloid leukemia (CML) with imatinib …
(clonal evolution, CE) during treatment of chronic myeloid leukemia (CML) with imatinib …
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine …
A Alhuraiji, H Kantarjian, P Boddu… - American journal of …, 2018 - Wiley Online Library
Additional cytogenetic abnormalities (ACA) are considered a high risk feature in chronic
myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the …
myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the …
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
RE Clark, JF Apperley, M Copland… - Blood Advances, 2021 - ashpublications.org
At diagnosis of chronic-phase chronic myeloid leukemia (CML), there are conflicting data as
to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia …
to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia …